Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03204188
Title Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

CLL/SLL

Therapies

Fludarabine + Ibrutinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST